MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.6 USD | -0.64% |
|
+0.58% | +18.83% |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Presenter SpeechGeoffrey Meacham (Analysts)Welcome to the second day of the Bank of America He...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.6
USD
Average target price
141.6
USD
Spread / Average Target
+9.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.83% | 330B | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 08